Literature DB >> 29214503

Epidemiology and clinical characteristics of human coronaviruses OC43, 229E, NL63, and HKU1: a study of hospitalized children with acute respiratory tract infection in Guangzhou, China.

Zhi-Qi Zeng1, De-Hui Chen2, Wei-Ping Tan3, Shu-Yan Qiu1, Duo Xu1, Huan-Xi Liang1, Mei-Xin Chen1, Xiao Li1, Zheng-Shi Lin1, Wen-Kuan Liu4, Rong Zhou5.   

Abstract

Human coronaviruses (HCoV) OC43, 229E, NL63, and HKU1 are common respiratory viruses which cause various respiratory diseases, including pneumonia. There is a paucity of evidence on the epidemiology and clinical manifestations of these four HCoV strains worldwide. We collected 11,399 throat swabs from hospitalized children with acute respiratory tract infection from July 2009 to June 2016 in Guangzhou, China. These were tested for four strains of HCoV infection using real-time polymerase chain reaction (PCR). HCoV-positive patients were then tested for 11 other respiratory pathogens. 4.3% (489/11399) of patients were positive for HCoV, of which 3.0% were positive for OC43 (346/11399), 0.6% for 229E (65/11399), 0.5% for NL63 (60/11399), and 0.3% for HKU1 (38/11399). Patients aged 7-12 months had the highest prevalence of HCoV and OC43 when compared with other age groups (p < 0.001). The peak seasons of infection varied depending on the HCoV strain. Patients infected with a single strain of HCoV infection were less likely to present fever (≥ 38 °C) (p = 0.014) and more likely to present pulmonary rales (p = 0.043) than those co-infected with more than one HCoV strain or other respiratory pathogens. There were also significant differences in the prevalence of certain symptoms, including coughing (p = 0.032), pneumonia (p = 0.026), and abnormal pulmonary rales (p = 0.002) according to the strain of HCoV detected. This retrospective study of the prevalence of four HCoV strains and clinical signs among a large population of pediatric patients in a subtropical region of China provides further insight into the epidemiology and clinical features of HCoV.

Entities:  

Mesh:

Year:  2017        PMID: 29214503      PMCID: PMC5780525          DOI: 10.1007/s10096-017-3144-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


Introduction

Respiratory viral infections in humans, which can vary from common colds to severe respiratory disease, represent a significant global health burden and a pressing public health challenge in developing countries and among socioeconomically disadvantaged children in particular. Human coronaviruses (HCoV) OC43, 229E, NL63, and HKU1 are associated with a wide range of upper respiratory tract infections (URTI) and, occasionally, lower respiratory tract infections (LRTI), including pneumonia and bronchiolitis [1-4], particularly in children [5]. Although HCoV is widespread globally [6-8], the frequency of detection of its four major strains varies significantly both by geography and over time [9-13]. Despite these features of its epidemiology, few long-term studies of the prevalence of HCoV strains and their clinical manifestations have been undertaken [14-16]. This paucity of evidence has led to an incomplete characterization of the epidemiology and clinical presentation of HCoV across different contexts. To expand the existing evidence base and provide new insights into the epidemiology and clinical manifestations of HCoV in a subtropical region, we performed a 7-year study of four HCoV strains among hospitalized pediatric patients with acute respiratory tract infection (ARTI) in Guangzhou, China.

Materials and methods

Sample collection

Throat swabs were collected from pediatric patients (≤ 14 years old) hospitalized with ARTI at The First Affiliated Hospital of Guangzhou Medical University and Sun Yat-Sen Memorial Hospital from July 2009 to June 2016. Both hospitals, each with nearly 2000 beds, were located in urban areas in Guangzhou, the capital city of a province with a humid subtropical climate. A case of HCoV was defined when a patient presented at least two of the following symptoms: cough, pharyngeal discomfort, rhinobyon, rhinorrhea, sneeze, dyspnea, or diagnosed with pneumonia by chest radiography during the previous week. The respiratory samples were refrigerated at 2–8 °C in viral transport medium, transported on ice to the State Key Laboratory of Respiratory Diseases, and analyzed immediately or stored at − 80 °C before analysis. Cases were retrospectively categorized into three groups according to their clinical symptoms: URTI, influenza-like symptoms, and LRTI. Patients presenting with cough, expectoration, rhinorrhea, rhinobyon, sneeze, pharyngeal discomfort, or trachyphonia were classified as having URTI. Patients with fever (≥ 38 °C), chills, dizziness, headache, myalgia, or debilitation were classified as having influenza-like symptoms. Patients with bronchopneumonia, pneumonia, asthma, shortness of breath, chest tightness, chest pain, or abnormal pulmonary rales were classified as having LRTI. Bronchopneumonia and pneumonia were diagnosed with chest radiography. Other clinical symptoms were identified by common medical examinations and clinical descriptions.

Real-time PCR for HCoV detection

RNA was extracted from throat swab samples using the QIAamp Viral RNA Mini Kit (Qiagen, Shanghai, China), according to the manufacturer’s protocols. Samples were tested for four HCoV strains (HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1) using the TaqMan real-time PCR testing kit (Guangzhou HuYanSuo Medical Technology Co., Ltd.), as previously reported [17].

Detection of common respiratory pathogens in HCoV-positive patients

HCoV-positive samples were simultaneously tested using TaqMan real-time PCR assays (Guangzhou HuYanSuo Medical Technology Co., Ltd.) for the following 11 respiratory pathogens: influenza A virus (Flu A), influenza B virus (Flu B), respiratory syncytial virus (RSV), human bocavirus (HBoV), adenovirus (ADV), human rhinovirus (HRV), human metapneumovirus (HMPV), enterovirus (EV), Mycoplasma pneumoniae (MP), Chlamydia pneumoniae (CP), and four types of human parainfluenza virus (HPIV).

Statistical analysis

All data were analyzed with SPSS statistical software (version 19.0; SPSS Inc., Chicago, IL), as described previously [18]. The χ2 test and Fisher’s exact test were used for comparisons of data. All tests were two tailed and p < 0.05 was considered statistically significant.

Results

Detection of HCoV among patients with ARTI

A total of 11,399 hospitalized pediatric patients (≤ 14 years old) with ARTI were enrolled in this study between July 2009 and June 2016. The median age of the patients was 1.75 years (interquartile range, 0.75–3.83) and the male to female ratio was 1.82:1 (7361:4038). We found that 489 out of the 11,399 patients (4.3%) tested positive for HCoV. Of these, 346 (3%) were positive for HCoV-OC43, 65 (0.6%) for HCoV-229E, 60 (0.5%) for HCoV-NL63, and 38 (0.3%) for HCoV-HKU1. The median age of HCoV-positive patients was 1.25 years (interquartile range, 0.75–3) and the male to female ratio was 1.67:1 (306:183).

Co-infection in HCoV-positive patients

Samples from HCoV-positive patients were also tested for 11 other common respiratory pathogens. Of the 489 HCoV-positive patients, 258 (52.8%) were infected with only one HCoV strain, while 231 (47.2%) were found to be co-infected with one or more additional strains of HCoV or another respiratory pathogen (Table 1). Of these, the most frequently identified pathogens were Flu A (21.6%, 50/231) and RSV (21.6%, 50/231).
Table 1

Co-pathogen detection in human coronavirus-positive patients

Co-pathogena HCoV (n = 231)229E (n = 38)OC43 (n = 161)NL63 (n = 33)HKU1 (n = 19)
Flu A50 (21.6)7 (18.4)38 (23.6)4 (12.1)4 (21.1)
RSV50 (21.6)10 (26.3)29 (18.0)10 (30.3)3 (15.8)
MP39 (16.9)3 (7.9)27 (16.8)3 (9.1)8 (42.1)
HPIV33 (14.3)5 (13.2)27 (16.7)2 (6.1)1 (5.3)
ADV22 (9.5)3 (7.9)14 (8.7)5 (15.2)2 (10.5)
EV20 (8.6)4 (10.5)10 (6.2)6 (18.2)1 (5.3)
HBoV15 (6.5)c 9 (5.6)3 (9.1)3 (15.8)
HMPV15 (6.4)3 (7.9)14 (8.7)1 (3.0)
HRV13 (5.6)2 (5.3)10 (6.2)1 (3.0)
Flu B10 (4.3)9 (5.6)1 (5.3)
CP4 (1.7)3 (1.9)1 (3.0)
HCoVb 18 (7.8)15 (39.5)16 (9.9)4 (12.1)2 (10.5)
229E15 (9.3)2 (6.1)
OC4315 (39.5)2 (6.1)1 (5.2)
NL632 (5.2)2 (1.2)1 (5.2)
HKU11 (0.6)1 (3)

Data are presented as no. (%) of each group. Percentages sum to over 100% because some patients had more than one diagnosis

aFlu A, influenza A virus; Flu B, influenza B virus; ADV, adenovirus; HRV, human rhinovirus; HMPV, human metapneumovirus; EV, enterovirus; MP, Mycoplasma pneumoniae; RSV, respiratory syncytial virus; HBoV, human bocavirus; HPIV, human parainfluenza virus; CP, Chlamydia pneumoniae; HCoV, human coronavirus

bDetection of more than one strain of HCoV

cNot detected

Co-pathogen detection in human coronavirus-positive patients Data are presented as no. (%) of each group. Percentages sum to over 100% because some patients had more than one diagnosis aFlu A, influenza A virus; Flu B, influenza B virus; ADV, adenovirus; HRV, human rhinovirus; HMPV, human metapneumovirus; EV, enterovirus; MP, Mycoplasma pneumoniae; RSV, respiratory syncytial virus; HBoV, human bocavirus; HPIV, human parainfluenza virus; CP, Chlamydia pneumoniae; HCoV, human coronavirus bDetection of more than one strain of HCoV cNot detected

Age distribution of HCoV-positive patients

In this study, patients were divided into seven age groups: 0–3 months, 4–6 months, 7–12 months, 1–2 years, 3–5 years, 6–10 years, and 11–14 years. There were statistically significant differences in the prevalence of overall HCoV and of HCoV-OC43 by age group (p < 0.001). Patients aged 7–12 months had the highest prevalence of both overall HCoV (5.9%, 71/1203) and HCoV-OC43 (4.1%, 49/1203) compared with the other age groups (Fig. 1). There were no significant differences in the prevalence of HCoV-229E (p = 0.429) or HCoV-NL63 (p = 0.437). Too few cases of HCoV-HKU1 were identified to assess the age distribution for this strain.
Fig. 1

Age distribution of patients with human coronaviruses OC43, 229E, NL63, and HKU1. m: month(s); y: year(s)

Age distribution of patients with human coronaviruses OC43, 229E, NL63, and HKU1. m: month(s); y: year(s)

Seasonal distribution of HCoV cases

There was a clear seasonal pattern in the presentation of HCoV cases over the 7-year period (Fig. 2). The overall prevalence of HCoV among attending patients tended to be highest in the spring and autumn. During the study period, the months with the highest recorded prevalences were February 2011 (11.7%, 9/77), April 2011 (13.2%, 14/106), April 2012 (15.3%, 25/163), August 2012 (13.4%, 19/142), July 2013 (11.7%, 23/196), and January 2014 (11.0%, 17/154). These seasonal trends were primarily driven by cases of HCoV-OC43. The other strains had different seasonal patterns, with smaller, more sporadic outbreaks.
Fig. 2

Seasonal distribution of the four human coronavirus strains in pediatric patients with acute respiratory tract infection from July 2009 to June 2016. HCoV: human coronavirus; OC43: human coronavirus OC43; 229E: human coronavirus 229E; NL63: human coronavirus NL63; HKU1: human coronavirus HKU1

Seasonal distribution of the four human coronavirus strains in pediatric patients with acute respiratory tract infection from July 2009 to June 2016. HCoV: human coronavirus; OC43: human coronavirus OC43; 229E: human coronavirus 229E; NL63: human coronavirus NL63; HKU1: human coronavirus HKU1

Clinical presentations of HCoV-positive patients

Table 2 shows the prevalence of clinical symptoms among HCoV-positive patients (n = 489) according to whether they had a single HCoV infection (n = 258) or were co-infected (n = 231), and according to the strain of HCoV detected.
Table 2

Clinical characteristics of human coronavirus-positive patients

Clinical presentationInfection with HCoVDistributions of HCoV strain
Single HCoV (n = 258)Co-pathogen (n = 231) p-Valuea 229E (n = 65)OC43 (n = 346)NL63 (n = 60)HKU1 (n = 38) p-Valueb
Upper respiratory tract infection
 Cough214 (82.9)198 (85.7)0.40152 (80.0)298 (86.1)43 (71.7)33 (86.9) 0.032
 Expectoration87 (33.7)81 (35.0)0.75520 (30.8)119 (34.4)15 (25.0)18 (47.4)0.137
 Rhinorrhea87 (33.7)87 (37.7)0.36324 (36.9)123 (35.6)21 (35.0)13 (34.2)0.993
 Rhinobyon79 (30.6)69 (29.9)0.85722 (33.9)106 (30.6)15 (25.0)12 (31.6)0.747
 Sneeze10 (3.9)10 (4.3)0.8014 (6.2)16 (4.6)2 (3.4)0 (0)
 Pharyngeal discomfortc 17 (6.6)15 (6.5)0.9668 (12.3)22 (6.4)4 (6.8)3 (7.9)0.381
 Trachyphonia9 (3.5)0 (0)e 1 (1.5)3 (0.9)5 (8.3)0 (0)
Influenza-like symptoms
 Fever (≥ 38 °C)143 (55.4)153 (66.2) 0.014 38 (58.5)213 (61.6)32 (53.3)23 (60.5)0.662
 Chills8 (3.1)11 (4.8)0.3433 (4.6)16 (4.6)1 (1.7)1 (2.6)0.859
 Dizziness0 (0)1 (0.5)0 (0)1 (0.3)0 (0)0 (0)
 Headache2 (0.8)1 (0.5)0.9230 (0)3 (0.9)0 (0)0 (0)
 Myalgia0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)
 Debilitation1 (0.4)2 (0.9)0.9230 (0)3 (0.9)0 (0)0 (0)
Lower respiratory tract infection
 Bronchopneumonia47 (18.2)52 (22.5)0.23812 (18.5)79 (22.8)8 (13.3)6 (15.8)0.295
 Pneumonia26 (10.1)32 (13.9)0.19713 (20.0)34 (9.8)12 (20.0)6 (15.8) 0.026
 Asthma70 (27.1)64 (27.7)0.88716 (24.6)99 (28.6)13 (21.7)9 (23.7)0.632
 Shortness of breath35 (13.6)28 (12.1)0.6347 (10.8)42 (12.1)9 (15.0)6 (15.8)0.776
 Chest tightness1 (0.4)0 (0)0 (0)1 (0.3)0 (0)0 (0)
 Chest pain1 (0.4)1 (0.4)0.9260 (0)2 (0.5)0 (0)0 (0)
 Abnormal pulmonary ralesd 164 (63.6)126 (54.5) 0.043 30 (46.2)193 (55.8)18 (30.0)19 (50.0) 0.002

Data are presented as no. (%) of each group. Percentages sum to over 100% because some patients had more than one diagnosis. Significant differences in bold

aTwo-tailed χ2 test, testing the distribution of each illness or diagnosis between patients infected with a single HCoV type and those co-infected with other type of HCoV or other respiratory pathogen

bTwo-tailed χ2 test, testing the distribution of each illness or diagnosis between the four HCoV types

cIncluding pharyngeal dryness and pharyngalgia

dIncluding phlegm rale, wheeze rale, bubbling rale, moist rale, and laryngeal stridor

eNot performed due to small sample size

Clinical characteristics of human coronavirus-positive patients Data are presented as no. (%) of each group. Percentages sum to over 100% because some patients had more than one diagnosis. Significant differences in bold aTwo-tailed χ2 test, testing the distribution of each illness or diagnosis between patients infected with a single HCoV type and those co-infected with other type of HCoV or other respiratory pathogen bTwo-tailed χ2 test, testing the distribution of each illness or diagnosis between the four HCoV types cIncluding pharyngeal dryness and pharyngalgia dIncluding phlegm rale, wheeze rale, bubbling rale, moist rale, and laryngeal stridor eNot performed due to small sample size There were statistically significant differences in the prevalence of pulmonary rales and fever according to whether a patient was co-infected. While the prevalence of pulmonary rales was higher among patients with a single HCoV infection (63.6%, 164/258) than among co-infected patients (54.5%, 126/231) (p = 0.043), fever was more prevalent among co-infected patients (66.2%, 153/231) than those with only one HCoV strain (55.4%, 143/258) (p = 0.014). There were also significant differences in the prevalence of cough (p = 0.032), pneumonia (p = 0.026), and abnormal pulmonary rales (p = 0.002) according to the strain of HCoV detected.

Discussion

This retrospective study analyzed data from 11,399 hospitalized children (≤ 14 years old) presenting with ARTI in two large municipal hospitals over a 7-year period in Guangzhou, China. Given the present study’s duration and large sample size, our results represent an important addition to the evidence base on the epidemiology and clinical manifestations of HCoV. Of the 11,399 patients tested, we found that 489 (4.3%) were HCoV-positive and that the most prevalent strain of HCoV was OC43 (3.0%), followed by 229E (0.6%), NL63 (0.5%), and HKU1 (0.3%). These findings are consistent with the results of other studies around the world [11, 13, 19]. The most common co-infecting pathogens among HCoV-positive patients were Flu A and RSV (Table 1). Other recent studies have also reported that RSV, Flu A, and rhinoviruses are the most common pathogens that co-occur with HCoV, and that co-infection may influence the clinical presentation of HCoV-positive patients [4, 5, 19–21]. Consistent with studies conducted in other contexts, including America and Slovenia [16, 20], our results showed that the prevalence of HCoV was highest among patients aged 7–12 months (Fig. 1). This increased vulnerability to respiratory pathogens may be attributable to increased contact with pathogens as infants begin to explore their environment or the waning of maternal antibody levels in infants while the immune system remains underdeveloped [22-24]. HCoV is widespread globally and patterns of outbreaks vary according to locations and seasonal factors [4]. Our study found that HCoV prevalence among patients presenting with ARTI in Guangzhou over a 7-year period was highest in the spring and autumn (Fig. 2). This stands in contrast to other studies which find higher prevalence of HCoV infection in winter and spring [16, 20]. We also found different seasonal prevalence patterns for each of the four HCoV strains, with peak frequencies of 229E, NL63, and OC43 occurring mostly in the spring and autumn in Guangzhou, although OC43 had lower peaks appearing in July 2012 and 2013, however (Fig. 2). Other studies conducted in Hong Kong have shown that, while the highest frequencies of NL63 and OC43 cases occurred in autumn and winter during the period 2005–2007 [25], OC43 and HKU1 cases peaked in winter and NL63 prevalence was highest in summer and autumn during the period 2004–2005 [14]. In the United States, 229E, OC43, and HKU1 have been shown to follow different seasonal patterns, with outbreaks of 229E occurring in winter, OC43 in spring and autumn, and HKU1 in summer [20]. Although these seasonal patterns vary between countries and over time, it is apparent across all studies that the prevalence of HCoV among children is lowest in early summer. Patients with HCoV infections presented a wide spectrum of respiratory symptoms. When we compared the clinical presentations of patients with a single HCoV infection to those with co-infections, we found that abnormal pulmonary rales occurred more frequently in the former group, while fever was more prevalent in the latter (Table 2). The results, therefore, indicate that patients infected with more than one respiratory pathogen are more likely to develop fever. Furthermore, abnormal pulmonary rales were more frequently detected among patients infected with OC43 than those infected with other strains. This suggests that HCoV-OC43 is more closely associated with LRTI. Patients with HCoV-OC43 also had the highest prevalence of broncho-pneumonia and asthma, although this was not significantly higher than among patients with other strains (Table 2). Our results are consistent with the findings of Lee and Storch [13] that HCoV-NL63 and HCoV-OC43 are associated with LRTI in children. However, Kuypers et al. [5] have found that, although HCoV-OC43 may be associated with asthma and some symptoms related to LRTI, other pathogens such as RSV may be more strongly implicated in cases of severe LRTI [26]. Recent studies have also shown that the most prevalent URTI symptoms among HCoV-positive individuals are fever, cough, sore throat, and headache [1, 19], and that LRTI including pneumonia and bronchiolitis also occasionally co-occur with HCoV [1, 5]. However, influenza-like symptoms were uncommon in our sample of HCoV-positive patients in this study. Our study has several strengths, including its large sample size and long duration. Furthermore, given that few studies to date have simultaneously tested for all four strains of HCoV in ARTI pediatric patients, the present study addresses an important gap in the literature. This study had some limitations, however. First, selection bias may have occurred due to the lack of healthy subjects without ARTI. Second, collecting biological samples using oropharyngeal swabs may be less reliable for detecting the presence of HCoV and other pathogens than obtaining bronchoalveolar lavage fluid. One advantage of this method, however, was that it is non-invasive and more suitable for routine analysis. In conclusion, the four strains of HCoV investigated in the present study are common among pediatric patients with ARTI in Guangzhou, China, and are often found alongside other respiratory pathogens. HCoV infection may cause a broad spectrum of symptoms, ranging from common cold-like symptoms, to influenza-like symptoms, asthma, and even pneumonia. The present study underscores the importance of HCoV infection in the etiology of pediatric ARTI, its relevance in clinical practice, and the pressing need to improve surveillance and detection in developing country contexts.
  26 in total

1.  Coronavirus HKU1 and other coronavirus infections in Hong Kong.

Authors:  Susanna K P Lau; Patrick C Y Woo; Cyril C Y Yip; Herman Tse; Hoi-wah Tsoi; Vincent C C Cheng; Paul Lee; Bone S F Tang; Chris H Y Cheung; Rodney A Lee; Lok-yee So; Yu-lung Lau; Kwok-hung Chan; Kwok-yung Yuen
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia.

Authors:  Patrick C Y Woo; Susanna K P Lau; Chung-ming Chu; Kwok-hung Chan; Hoi-wah Tsoi; Yi Huang; Beatrice H L Wong; Rosana W S Poon; James J Cai; Wei-kwang Luk; Leo L M Poon; Samson S Y Wong; Yi Guan; J S Malik Peiris; Kwok-yung Yuen
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, Japan.

Authors:  Yohei Matoba; Chieko Abiko; Tatsuya Ikeda; Yoko Aoki; Yu Suzuki; Kazue Yahagi; Yoko Matsuzaki; Tsutomu Itagaki; Fumio Katsushima; Yuriko Katsushima; Katsumi Mizuta
Journal:  Jpn J Infect Dis       Date:  2014-11-25       Impact factor: 1.362

4.  Epidemiology and clinical presentations of human coronavirus NL63 infections in hong kong children.

Authors:  Ting Fan Leung; Chung Yi Li; Wai Yip Lam; Gary W K Wong; Edmund Cheuk; Margaret Ip; Pak Cheung Ng; Paul K S Chan
Journal:  J Clin Microbiol       Date:  2009-09-16       Impact factor: 5.948

5.  Coronavirus HKU1 infection in the United States.

Authors:  Frank Esper; Carla Weibel; David Ferguson; Marie L Landry; Jeffrey S Kahn
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

6.  Epidemiology of acute respiratory infections in children in Guangzhou: a three-year study.

Authors:  Wen Kuan Liu; Qian Liu; De Hui Chen; Huan Xi Liang; Xiao Kai Chen; Mei Xin Chen; Shu Yan Qiu; Zi Yeng Yang; Rong Zhou
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

7.  Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients.

Authors:  Giuseppe Gerna; Elena Percivalle; Antonella Sarasini; Giulia Campanini; Antonio Piralla; Francesca Rovida; Emilia Genini; Antonietta Marchi; Fausto Baldanti
Journal:  J Clin Virol       Date:  2007-01-10       Impact factor: 3.168

8.  An outbreak of coronavirus OC43 respiratory infection in Normandy, France.

Authors:  Astrid Vabret; Thomas Mourez; Stéphanie Gouarin; Joëlle Petitjean; François Freymuth
Journal:  Clin Infect Dis       Date:  2003-04-04       Impact factor: 9.079

Review 9.  Human coronavirus NL63, a new respiratory virus.

Authors:  Lia van der Hoek; Krzysztof Pyrc; Ben Berkhout
Journal:  FEMS Microbiol Rev       Date:  2006-09       Impact factor: 16.408

10.  Detection of four human coronaviruses in respiratory infections in children: a one-year study in Colorado.

Authors:  Samuel R Dominguez; Christine C Robinson; Kathryn V Holmes
Journal:  J Med Virol       Date:  2009-09       Impact factor: 2.327

View more
  59 in total

1.  A Single and Two-Stage, Closed-Tube, Molecular Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry.

Authors:  Mohamed El-Tholoth; Haim H Bau; Jinzhao Song
Journal:  ChemRxiv       Date:  2020-02-19

2.  COVID-19 in Ophthalmology. Current Disease Status and Challenges during Clinical Practice.

Authors:  Georgios Bontzos; Anastasia Gkiala; Christina Karakosta; Neofytos Maliotis; Efstathios T Detorakis
Journal:  Maedica (Bucur)       Date:  2021-12

Review 3.  Antiviral performance of graphene-based materials with emphasis on COVID-19: A review.

Authors:  Tahereh Seifi; Ali Reza Kamali
Journal:  Med Drug Discov       Date:  2021-05-25

4.  Epidemiology and clinical features of common community human coronavirus disease.

Authors:  Taehee Kim; Hayoung Choi; Tae Rim Shin; Yousang Ko; Yong Bum Park; Hwan Il Kim; Seung Hun Jang; Ki Suck Jung; Youlim Kim; Myung Goo Lee; Soojie Chung; Cheol-Hong Kim; In Gyu Hyun; Yun Su Sim
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 2.895

5.  The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor.

Authors:  Esther S Brielle; Dina Schneidman-Duhovny; Michal Linial
Journal:  Viruses       Date:  2020-04-30       Impact factor: 5.048

Review 6.  Risk Factors for Severity in Children with Coronavirus Disease 2019: A Comprehensive Literature Review.

Authors:  Sophia Tsabouri; Alexandros Makis; Chrysoula Kosmeri; Ekaterini Siomou
Journal:  Pediatr Clin North Am       Date:  2020-07-30       Impact factor: 3.278

Review 7.  Could Nanotheranostics be the Answer to the Coronavirus Crisis?

Authors:  Dina A Mosselhy; Mhd Adel Assad; Tarja Sironen; Mady Elbahri
Journal:  Glob Chall       Date:  2021-03-24

8.  The epidemiology and etiologies of respiratory tract infection in Northern Taiwan during the early phase of coronavirus disease 2019 (COVID-19) outbreak.

Authors:  Andrew Po-Liang Chen; Chien Chuang; Ying-Chi Huang; Ping-Feng Wu; Shiang-Fen Huang; Nai-Cheng Cheng; Yi-Tsung Lin; Su-Jung Chen; Ling-Ju Huang; Chia-Lin Lee; Hsin-Pai Chen; Yu-Jiun Chan; Fu-Der Wang
Journal:  J Microbiol Immunol Infect       Date:  2021-06-22       Impact factor: 4.399

9.  Epidemiology and Clinical Symptoms Related to Seasonal Coronavirus Identified in Patients with Acute Respiratory Infections Consulting in Primary Care over Six Influenza Seasons (2014-2020) in France.

Authors:  Shirley Masse; Lisandru Capai; Natacha Villechenaud; Thierry Blanchon; Rémi Charrel; Alessandra Falchi
Journal:  Viruses       Date:  2020-06-10       Impact factor: 5.048

10.  A Single and Two-Stage, Closed-Tube, Molecular Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry.

Authors:  Mohamed El-Tholoth; Haim H Bau; Jinzhao Song
Journal:  ChemRxiv       Date:  2020-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.